Dr Reddys Laboratories Stock Fundamentals
| RDY Stock | USD 14.14 0.06 0.43% |
Dr Reddys Laboratories fundamentals help investors to digest information that contributes to Dr Reddys' financial success or failures. It also enables traders to predict the movement of RDY Stock. The fundamental analysis module provides a way to measure Dr Reddys' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Dr Reddys stock.
At this time, Dr Reddys' Depreciation And Amortization is fairly stable compared to the past year. Other Operating Expenses is likely to rise to about 222 B in 2024, whereas Selling General Administrative is likely to drop slightly above 73.3 B in 2024. RDY | Select Account or Indicator |
Dr Reddys Laboratories Company Return On Equity Analysis
Dr Reddys' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Dr Reddys Return On Equity | 0.19 |
Most of Dr Reddys' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Dr Reddys Laboratories is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
RDY Return On Equity Historical Pattern
Today, most investors in Dr Reddys Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Dr Reddys' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's return on equity growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Dr Reddys return on equity as a starting point in their analysis.
Dr Reddys Return On Equity |
| Timeline |
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
RDY Total Stockholder Equity
Total Stockholder Equity |
|
Based on the latest financial disclosure, Dr Reddys Laboratories has a Return On Equity of 0.1927. This is 100.8% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The return on equity for all United States stocks is 162.16% lower than that of the firm.
Dr Reddys Laboratories Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Dr Reddys's current stock value. Our valuation model uses many indicators to compare Dr Reddys value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Dr Reddys competition to find correlations between indicators driving Dr Reddys's intrinsic value. More Info.Dr Reddys Laboratories is currently regarded as top stock in return on equity category among its peers. It also is currently regarded as top stock in return on asset category among its peers reporting about 0.54 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Dr Reddys Laboratories is roughly 1.85 . At this time, Dr Reddys' Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Dr Reddys' earnings, one of the primary drivers of an investment's value.RDY Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Dr Reddys' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Dr Reddys could also be used in its relative valuation, which is a method of valuing Dr Reddys by comparing valuation metrics of similar companies.Dr Reddys is currently under evaluation in return on equity category among its peers.
Dr Reddys Current Valuation Drivers
We derive many important indicators used in calculating different scores of Dr Reddys from analyzing Dr Reddys' financial statements. These drivers represent accounts that assess Dr Reddys' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Dr Reddys' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 92.7B | 103.5B | 142.5B | 153.5B | 1.0T | 1.1T | |
| Enterprise Value | 128.9B | 123.5B | 161.5B | 161.2B | 1.1T | 1.1T |
Dr Reddys ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Dr Reddys' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Dr Reddys' managers, analysts, and investors.Environmental | Governance | Social |
RDY Fundamentals
| Return On Equity | 0.19 | ||||
| Return On Asset | 0.1 | ||||
| Profit Margin | 0.18 % | ||||
| Operating Margin | 0.23 % | ||||
| Current Valuation | 11.69 B | ||||
| Shares Outstanding | 833.05 M | ||||
| Shares Owned By Institutions | 14.22 % | ||||
| Number Of Shares Shorted | 11.64 M | ||||
| Price To Earning | 31.58 X | ||||
| Price To Book | 3.24 X | ||||
| Price To Sales | 0.04 X | ||||
| Revenue | 279.16 B | ||||
| Gross Profit | 113.84 B | ||||
| EBITDA | 88.42 B | ||||
| Net Income | 55.68 B | ||||
| Cash And Equivalents | 2.93 B | ||||
| Cash Per Share | 208.58 X | ||||
| Total Debt | 20.02 B | ||||
| Debt To Equity | 0.12 % | ||||
| Current Ratio | 1.98 X | ||||
| Book Value Per Share | 366.54 X | ||||
| Cash Flow From Operations | 45.43 B | ||||
| Short Ratio | 15.46 X | ||||
| Earnings Per Share | 0.79 X | ||||
| Price To Earnings To Growth | 4.51 X | ||||
| Target Price | 1304.45 | ||||
| Number Of Employees | 27.05 K | ||||
| Beta | 0.33 | ||||
| Market Capitalization | 11.86 B | ||||
| Total Asset | 387.52 B | ||||
| Retained Earnings | 265.26 B | ||||
| Working Capital | 152.01 B | ||||
| Current Asset | 1.81 B | ||||
| Current Liabilities | 976 M | ||||
| Annual Yield | 0.01 % | ||||
| Five Year Return | 0.72 % | ||||
| Net Asset | 387.52 B | ||||
| Last Dividend Paid | 8.0 |
About Dr Reddys Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Dr Reddys Laboratories's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Dr Reddys using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Dr Reddys Laboratories based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 1.4 B | 1.4 B | |
| Total Revenue | 279.2 B | 293.1 B | |
| Cost Of Revenue | 115.6 B | 121.3 B | |
| Sales General And Administrative To Revenue | 0.17 | 0.15 | |
| Research And Ddevelopement To Revenue | 0.08 | 0.07 | |
| Capex To Revenue | 0.10 | 0.07 | |
| Revenue Per Share | 335.55 | 481.86 | |
| Ebit Per Revenue | 0.24 | 0.25 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for RDY Stock Analysis
When running Dr Reddys' price analysis, check to measure Dr Reddys' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dr Reddys is operating at the current time. Most of Dr Reddys' value examination focuses on studying past and present price action to predict the probability of Dr Reddys' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dr Reddys' price. Additionally, you may evaluate how the addition of Dr Reddys to your portfolios can decrease your overall portfolio volatility.